Insider Selling: Heartflow (NASDAQ:HTFL) CEO Sells $1,361,500.00 in Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 38,900 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $35.00, for a total value of $1,361,500.00. Following the completion of the transaction, the chief executive officer directly owned 457,935 shares of the company’s stock, valued at approximately $16,027,725. The trade was a 7.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

• On Wednesday, June 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $28.50, for a total value of $643,017.00.
• On Monday, May 11th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $29.12, for a total transaction of $657,005.44.
• On Friday, April 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $26.72, for a total transaction of $602,856.64.

Heartflow Trading Up 2.0%

Shares of Heartflow stock traded up $0.70 during mid-day trading on Friday, reaching $35.68. 12,523,558 shares of the stock were exchanged, compared to its average volume of 1,466,069. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $41.22. The company has a market cap of $3.08 billion and a price-to-earnings ratio of -11.47. The firm has a 50-day simple moving average of $30.57 and a 200 day simple moving average of $28.55.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.08. The firm had revenue of $52.59 million for the quarter. The company’s revenue was up 41.3% compared to the same quarter last year. On average, research analysts predict that Heartflow, Inc. will post -0.82 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Piper Sandler reissued an “overweight” rating on shares of Heartflow in a research note on Thursday, June 11th. JPMorgan Chase & Co. lowered their target price on Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, March 19th. Weiss Ratings upgraded shares of Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. Wells Fargo & Company increased their price objective on shares of Heartflow from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Finally, Canaccord Genuity Group lowered their price objective on shares of Heartflow from $43.00 to $37.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $37.00.

Institutional Investors Weigh In On Heartflow

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP bought a new stake in shares of Heartflow during the third quarter worth $164,263,000. Schusterman Interests LLC acquired a new stake in Heartflow in the third quarter worth about $65,274,000. Capricorn Investment Group LLC bought a new stake in Heartflow during the 4th quarter worth about $48,178,000. Vanguard Group Inc. acquired a new position in Heartflow during the 3rd quarter valued at about $48,871,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Heartflow during the 4th quarter valued at about $41,714,000.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.